Business Description
BiVictriX Therapeutics PLC
ISIN : GB00BNXH3K91
Description
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.52 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -77.3 | |||||
| 3-Year EPS without NRI Growth Rate | -71 | |||||
| 3-Year FCF Growth Rate | -108 | |||||
| 3-Year Book Growth Rate | 250.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.22 | |||||
| 9-Day RSI | 75.08 | |||||
| 14-Day RSI | 71.25 | |||||
| 6-1 Month Momentum % | 23.3 | |||||
| 12-1 Month Momentum % | -21.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.12 | |||||
| Quick Ratio | 6.12 | |||||
| Cash Ratio | 5.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.7 | |||||
| Shareholder Yield % | 0.39 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -73.94 | |||||
| ROA % | -62.13 | |||||
| ROIC % | -234.12 | |||||
| ROC (Joel Greenblatt) % | -321.35 | |||||
| ROCE % | -83.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.02 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| EV-to-EBIT | -2.55 | |||||
| EV-to-EBITDA | -2.7 | |||||
| EV-to-FCF | -3.92 | |||||
| Price-to-Net-Current-Asset-Value | 3.5 | |||||
| Price-to-Net-Cash | 4.67 | |||||
| Earnings Yield (Greenblatt) % | -39.22 | |||||
| FCF Yield % | -18.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BiVictriX Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.041 | ||
| Beta | 0 | ||
| Volatility % | 35.28 | ||
| 14-Day RSI | 71.25 | ||
| 14-Day ATR (€) | 0.002916 | ||
| 20-Day SMA (€) | 0.13795 | ||
| 12-1 Month Momentum % | -21.12 | ||
| 52-Week Range (€) | 0.102 - 0.162 | ||
| Shares Outstanding (Mil) | 82.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BiVictriX Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BiVictriX Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BiVictriX Therapeutics PLC Frequently Asked Questions
What is BiVictriX Therapeutics PLC(FRA:4DE)'s stock price today?
The current price of FRA:4DE is €0.14. The 52 week high of FRA:4DE is €0.16 and 52 week low is €0.10.
When is next earnings date of BiVictriX Therapeutics PLC(FRA:4DE)?
The next earnings date of BiVictriX Therapeutics PLC(FRA:4DE) is 2024-09-19 Est..
Does BiVictriX Therapeutics PLC(FRA:4DE) pay dividends? If so, how much?
BiVictriX Therapeutics PLC(FRA:4DE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers